XML 44 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2021
Segment Information  
Summary of results of operations by reportable segment

    

Prescription 

    

Medical 

    

    

For the six months ended June 30, 2021

Medications

Devices

Corporate

Consolidated

Net sales

$

4,850,462

$

1,682,793

$

$

6,533,255

Cost of goods sold

 

562,328

 

474,352

 

 

1,036,680

Selling, general and administrative expenses

 

3,666,993

 

1,291,426

 

3,039,471

 

7,997,890

Research and development expenses

 

519,227

 

 

 

519,227

Depreciation and amortization expense

 

2,796,539

 

661,118

 

 

3,457,657

Change in fair value of derivative liability

 

 

 

(7,670,000)

 

(7,670,000)

Interest expense

 

 

 

288,937

 

288,937

Income tax expense

 

 

(6,700)

 

 

(6,700)

Net income (loss)

$

(2,694,625)

$

(750,803)

$

4,341,592

$

896,164

Prescription 

    

Medical 

    

    

For the six months ended June 30, 2020

Medications

    

Devices

    

Corporate

    

Consolidated

Net sales

$

1,538,543

$

1,626,942

$

$

3,165,485

Cost of goods sold

 

777,594

 

545,672

 

 

1,323,266

Selling, general and administrative expenses

 

4,820,367

 

1,213,864

 

2,841,931

 

8,876,162

Research and development expense

 

270,968

 

 

 

270,968

Depreciation and amortization expense

 

2,707,181

 

615,541

 

 

3,322,722

Interest expense

 

 

 

1,263,709

 

1,263,709

Income tax benefit

 

 

43,752

 

 

43,752

Net loss

$

(7,037,567)

$

(704,383)

$

(4,105,640)

$

(11,847,590)

Summary of net sales by geographic region

For the Three Months Ended

For the Six Months Ended

June 30, 

June 30, 

Net sales

    

2021

    

2020

    

2021

    

2020

United States

$

2,188,789

$

1,205,973

$

5,893,312

$

2,654,593

International

 

268,860

 

167,591

639,943

510,892

$

2,457,649

$

1,373,564

$

6,533,255

$

3,165,485

Summary of assets by reportable segment and reconciliation of segment assets to consolidated assets

Prescription 

    

    

    

Medications

    

Medical Devices

    

Consolidated

Intangible assets, net

$

21,834,257

$

6,874,115

$

28,708,372

Total segment assets

$

47,850,814

$

8,819,430

$

56,670,244

Prescription 

    

Medications

    

Medical Devices

    

Consolidated

Intangible assets, net

$

24,625,686

$

7,535,233

$

32,160,919

Total segment assets

$

60,725,191

$

9,128,823

$

69,854,014